Production (Stage)
Fulcrum Therapeutics, Inc.
FULC
$6.85
$0.071.03%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 34.29% | 33.07% | 9.66% | 332.98% | -8.44% |
| Total Depreciation and Amortization | -26.30% | -27.36% | -30.51% | -33.69% | -15.37% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -17.68% | -27.77% | 23.84% | 94.43% | -4.57% |
| Change in Net Operating Assets | 86.47% | -103.10% | 73.92% | -112.31% | 40.93% |
| Cash from Operations | 39.66% | 27.62% | 16.74% | 383.37% | -4.84% |
| Capital Expenditure | -- | -200.00% | 70.77% | 100.00% | 83.63% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -102.04% | -86.48% | -77.11% | -162.32% | 140.69% |
| Cash from Investing | -102.04% | -87.69% | -77.13% | -162.93% | 140.59% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -71.08% | -- | 165.49% | -98.60% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -71.08% | -- | 165.49% | -98.60% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -210.62% | -219.19% | -262.51% | 6,189.58% | 4,082.14% |